Sitagliptin Treatment After Total Pancreatectomy With Islet Autotransplantation: A Randomized, Placebo-Controlled Study

Melena D Bellin, Gregory J Beilman, Ty B Dunn, Timothy L Pruett, D. E.R. Sutherland, Srinath Chinnakotla, James S Hodges, A. Lane, P. Ptacek, K. L. Berry, Bernhard J Hering, Antoinette Moran

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Insulin independence after total pancreatectomy and islet autotransplant (TPIAT) for chronic pancreatitis is limited by a high rate of postprocedure beta cell apoptosis. Endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are increased by dipeptidyl peptidase 4 inhibitor therapy (sitagliptin) may protect against beta cell apoptosis. To determine the effect of sitagliptin after TPIAT, 83 adult TPIAT recipients were randomized to receive sitagliptin (n = 54) or placebo (n = 29) for 12 months after TPIAT. At 12 and 18 months after TPIAT, participants were assessed for insulin independence; metabolic testing was performed with mixed meal tolerance testing and frequent sample intravenous glucose tolerance testing. Insulin independence did not differ between the sitagliptin and placebo groups at 12 months (42% vs. 45%, p = 0.82) or 18 months (36% vs. 44%, p = 0.48). At 12 months, insulin dose was 9.0 (standard error 1.7) units/day and 7.9 (2.2) units/day in the sitagliptin and placebo groups, respectively (p = 0.67) and at 18 months 10.3 (1.9) and 7.1 (2.6) units/day, respectively (p = 0.32). Hemoglobin A1c levels and insulin secretory measures were similar in the two groups, as were adverse events. In conclusion, sitagliptin could be safely administered but did not improve metabolic outcomes after TPIAT.

Original languageEnglish (US)
Pages (from-to)443-450
Number of pages8
JournalAmerican Journal of Transplantation
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Pancreatectomy
Autologous Transplantation
Autografts
Placebos
Insulin
Therapeutics
Gastric Inhibitory Polypeptide
Dipeptidyl-Peptidase IV Inhibitors
Apoptosis
Glucagon-Like Peptide 1
Chronic Pancreatitis
Glucose Tolerance Test
Meals
Sitagliptin Phosphate
Hemoglobins

Keywords

  • clinical research/practice
  • clinical trial
  • diabetes
  • graft survival
  • insulin/C-peptide
  • islet transplantation
  • islets of Langerhans

Cite this

@article{8846710b3bc544c8bb04c0855cb8ec83,
title = "Sitagliptin Treatment After Total Pancreatectomy With Islet Autotransplantation: A Randomized, Placebo-Controlled Study",
abstract = "Insulin independence after total pancreatectomy and islet autotransplant (TPIAT) for chronic pancreatitis is limited by a high rate of postprocedure beta cell apoptosis. Endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are increased by dipeptidyl peptidase 4 inhibitor therapy (sitagliptin) may protect against beta cell apoptosis. To determine the effect of sitagliptin after TPIAT, 83 adult TPIAT recipients were randomized to receive sitagliptin (n = 54) or placebo (n = 29) for 12 months after TPIAT. At 12 and 18 months after TPIAT, participants were assessed for insulin independence; metabolic testing was performed with mixed meal tolerance testing and frequent sample intravenous glucose tolerance testing. Insulin independence did not differ between the sitagliptin and placebo groups at 12 months (42{\%} vs. 45{\%}, p = 0.82) or 18 months (36{\%} vs. 44{\%}, p = 0.48). At 12 months, insulin dose was 9.0 (standard error 1.7) units/day and 7.9 (2.2) units/day in the sitagliptin and placebo groups, respectively (p = 0.67) and at 18 months 10.3 (1.9) and 7.1 (2.6) units/day, respectively (p = 0.32). Hemoglobin A1c levels and insulin secretory measures were similar in the two groups, as were adverse events. In conclusion, sitagliptin could be safely administered but did not improve metabolic outcomes after TPIAT.",
keywords = "clinical research/practice, clinical trial, diabetes, graft survival, insulin/C-peptide, islet transplantation, islets of Langerhans",
author = "Bellin, {Melena D} and Beilman, {Gregory J} and Dunn, {Ty B} and Pruett, {Timothy L} and Sutherland, {D. E.R.} and Srinath Chinnakotla and Hodges, {James S} and A. Lane and P. Ptacek and Berry, {K. L.} and Hering, {Bernhard J} and Antoinette Moran",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/ajt.13979",
language = "English (US)",
volume = "17",
pages = "443--450",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Sitagliptin Treatment After Total Pancreatectomy With Islet Autotransplantation

T2 - A Randomized, Placebo-Controlled Study

AU - Bellin, Melena D

AU - Beilman, Gregory J

AU - Dunn, Ty B

AU - Pruett, Timothy L

AU - Sutherland, D. E.R.

AU - Chinnakotla, Srinath

AU - Hodges, James S

AU - Lane, A.

AU - Ptacek, P.

AU - Berry, K. L.

AU - Hering, Bernhard J

AU - Moran, Antoinette

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Insulin independence after total pancreatectomy and islet autotransplant (TPIAT) for chronic pancreatitis is limited by a high rate of postprocedure beta cell apoptosis. Endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are increased by dipeptidyl peptidase 4 inhibitor therapy (sitagliptin) may protect against beta cell apoptosis. To determine the effect of sitagliptin after TPIAT, 83 adult TPIAT recipients were randomized to receive sitagliptin (n = 54) or placebo (n = 29) for 12 months after TPIAT. At 12 and 18 months after TPIAT, participants were assessed for insulin independence; metabolic testing was performed with mixed meal tolerance testing and frequent sample intravenous glucose tolerance testing. Insulin independence did not differ between the sitagliptin and placebo groups at 12 months (42% vs. 45%, p = 0.82) or 18 months (36% vs. 44%, p = 0.48). At 12 months, insulin dose was 9.0 (standard error 1.7) units/day and 7.9 (2.2) units/day in the sitagliptin and placebo groups, respectively (p = 0.67) and at 18 months 10.3 (1.9) and 7.1 (2.6) units/day, respectively (p = 0.32). Hemoglobin A1c levels and insulin secretory measures were similar in the two groups, as were adverse events. In conclusion, sitagliptin could be safely administered but did not improve metabolic outcomes after TPIAT.

AB - Insulin independence after total pancreatectomy and islet autotransplant (TPIAT) for chronic pancreatitis is limited by a high rate of postprocedure beta cell apoptosis. Endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are increased by dipeptidyl peptidase 4 inhibitor therapy (sitagliptin) may protect against beta cell apoptosis. To determine the effect of sitagliptin after TPIAT, 83 adult TPIAT recipients were randomized to receive sitagliptin (n = 54) or placebo (n = 29) for 12 months after TPIAT. At 12 and 18 months after TPIAT, participants were assessed for insulin independence; metabolic testing was performed with mixed meal tolerance testing and frequent sample intravenous glucose tolerance testing. Insulin independence did not differ between the sitagliptin and placebo groups at 12 months (42% vs. 45%, p = 0.82) or 18 months (36% vs. 44%, p = 0.48). At 12 months, insulin dose was 9.0 (standard error 1.7) units/day and 7.9 (2.2) units/day in the sitagliptin and placebo groups, respectively (p = 0.67) and at 18 months 10.3 (1.9) and 7.1 (2.6) units/day, respectively (p = 0.32). Hemoglobin A1c levels and insulin secretory measures were similar in the two groups, as were adverse events. In conclusion, sitagliptin could be safely administered but did not improve metabolic outcomes after TPIAT.

KW - clinical research/practice

KW - clinical trial

KW - diabetes

KW - graft survival

KW - insulin/C-peptide

KW - islet transplantation

KW - islets of Langerhans

UR - http://www.scopus.com/inward/record.url?scp=84983554769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983554769&partnerID=8YFLogxK

U2 - 10.1111/ajt.13979

DO - 10.1111/ajt.13979

M3 - Article

C2 - 27459721

AN - SCOPUS:84983554769

VL - 17

SP - 443

EP - 450

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 2

ER -